On August 25, 2026, Hepion Pharmaceuticals entered into securities purchase agreements with accredited investors to sell and issue 8,000,000 shares of common stock and warrants to purchase an additional 8,000,000 shares in a private placement. The offering price was $0.05 per share, generating gross proceeds of $400,000. The accompanying warrants are exercisable at $0.06 per share for five years from issuance. This transaction was conducted under Section 4(a)(2) and Regulation D exemptions. Hepion Pharmaceuticals operates in the biotechnology industry, focusing on drug discovery and development.
